Gastric microbiota in the functional dyspepsia patients treated with probiotic yogurt

Nakae, Hirohiko; Tsuda, Ayumi; Matsuoka, Takashi; Mine, Tetsuya; Koga, Yuichi

doi:10.1136/bmjgast-2016-000109

Cited by 67 publications

(80 citation statements)

References 21 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, the abundance of Prevotella spp. in the gastric microbiota was inversely associated with the severity of PDS symptoms in a small study 101 . Another small study analysed the composition of the gastric microbiota in patients with functional dyspepsia and reported that Bacteroidetes were more abundant than Proteobacteria compared with healthy controls, and Acidobacteria were absent 102 , whereas another study described an altered duodenal microbiota with a predominance of species typically found in the oral microbiota 103 .…”

Section: Intestinal Microbiotamentioning

confidence: 86%

Functional dyspepsia

Enck¹,

Azpiroz

Boeckxstaens

et al. 2017

Nat Rev Dis Primers

253

247

View full text Add to dashboard Cite

| Functional dyspepsia is one of the most prevalent functional gastrointestinal disorders. Functional dyspepsia comprises three subtypes with presumed different pathophysiology and aetiology: postprandial distress syndrome (PDS), epigastric pain syndrome (EPS) and a subtype with overlapping PDS and EPS features. Functional dyspepsia symptoms can be caused by disturbed gastric motility (for example, inadequate fundic accommodation or delayed gastric emptying), gastric sensation (for example, sensations associated with hypersensitivity to gas and bloating) or gastric and duodenal inflammation. A genetic predisposition is probable but less evident than in other functional gastrointestinal disorders, such as irritable bowel syndrome (IBS). Psychiatric comorbidity and psychopathological state and trait characteristics could also play a part, although they are not specific to functional dyspepsia and are less pronounced than in IBS. Possible differential diagnoses include Helicobacter pylori infection and peptic ulceration. Pharmacological therapy is mostly based on the subtype of functional dyspepsia, such as prokinetic and fundus-relaxing drugs for PDS and acid-suppressive drugs for EPS, whereas centrally active neuromodulators and herbal drugs play a minor part. Psychotherapy is effective only in a small subset of patients, whereas quality of life can be severely affected in nearly all patients. Future therapies might include novel compounds that attempt to treat the underlying gastric and duodenal inflammation. NATURE REVIEWS | DISEASE PRIMERS VOLUME 3 | ARTICLE NUMBER 17081 | 1 PRIMER © 2 0 1 7 M a c m i l l a n P u b l i s h e r s L i m i t e d , p a r t o f S p r i n g e r N a t u r e . A l l r i g h t s r e s e r v e d .standard therapy for gastro -oesophageal reflux disease. Paediatric dyspeptic symptoms are being addressed in a separate classification effort 10 . This Primer covers functional dyspepsia in adults only, although we sporadically refer to paediatric functional dyspepsia when similarities exist. EpidemiologyThe population prevalence of functional dyspepsia is quite variable across the globe, with overall high numbers (10-40%) in Western countries and low numbers (5-30%) in Asia, independent of the respective functional dyspepsia definitions 11 . A large-scale health and nutrition survey from France 12 (which involved >35,000 people) identified that 15% of individuals had suspected functional dyspepsia, 28% had irritable bowel syndrome (IBS) and 6% had both. The population of patients who are affected by both IBS and functional dyspepsia has been reported to range between 10% and 27% in previous studies 13 and to approach 30% in popu lation samples; it could be even higher in specific populations 14,15 . This observation has given rise to the term 'overlap syndrome' (REF. 13), which calls into question the sensitivity and specificity of the Rome criteria, at least for IBS and functional dyspepsia. This argument is also supported by the observation that patients with functional dyspepsia m...

show abstract

Section: Intestinal Microbiotamentioning

confidence: 86%

Functional dyspepsia

Enck¹,

Azpiroz

Boeckxstaens

et al. 2017

Nat Rev Dis Primers

253

247

View full text Add to dashboard Cite

show abstract

“…Therefore, it is necessary to investigate whether L. gasseri OLL2716 is involved in the improvement of bowel disorders and its efficacy in the improvement of FD. Interestingly, a recent report showed that Bifidobacterium and Clostridum , which are both intestinal bacteria, are detected in the gastric juice of patients with FD [39]. In the future, there is a need to elucidate at which sites between the stomach and the intestine L. gasseri OLL2716 acts, and whether indigenous bacterial flora are involved in the process.…”

Section: Discussionmentioning

confidence: 99%

The Ameliorating Effect of Lactobacillus gasseri OLL2716 on Functional Dyspepsia in Helicobacter pylori-Uninfected Individuals: A Randomized Controlled Study

Ohtsu

Takagi²,

Uemura

et al. 2017

Digestion

Self Cite

View full text Add to dashboard Cite

Background/Aims: Probiotics appear to improve Helicobacter pylori-associated dyspepsia via an inhibitory effect on H. pylori; however, uncertainty exists regarding their effects in H. pylori-uninfected individuals. We evaluated the efficacy of Lactobacillus gasseri OLL2716 (L. gasseri OLL2716) on H. pylori-uninfected individuals with functional dyspepsia (FD). Methods: A double-blind, parallel-group, placebo-controlled, randomized, controlled trial was performed. Participants were randomly assigned to ingest L. gasseri OLL2716-containing yogurt (L. gasseri OLL2716 group) or L. gasseri OLL2716-free yogurt (placebo group) for 12 weeks. Participants completed questionnaires that dealt with a global assessment as well as symptom severity. The per-protocol (PP) population was evaluated for efficacy in accordance with a plan prepared beforehand. Results: Randomization was performed on 116 individuals; the PP population consisted of 106 individuals (mean age 42.8 ± 9.0). The impressions regarding the overall effect on gastric symptoms were more positive in the L. gasseri OLL2716 group compared to that in the placebo group (statistical trend; p = 0.073). The elimination rate for major FD symptoms was 17.3 and 35.3% in the placebo and L. gasseri OLL2716 groups respectively (p = 0.048). Conclusion:L. gasseri OLL2716 has beneficial effects on FD without H. pylori involvement.

show abstract

“…A significant inverse correlation was reported between an abundance of Prevotella sp. and severity of postprandial distress‐like syndromes and treatment of FD patients with a yogurt containing a probiotic strain of Lactobacillus gasseri daily for a 12‐week period reversed the dysbiosis and relieved their symptoms . The administration of probiotics for correction of gastric dysbiosis may be a rational and promising direction for the treatment of FD.…”

Section: Gastric and Gut Microbiotamentioning

confidence: 99%

“…In another study, Helicobacteraceae decreased with a probiotic cocktail ( Lactobacillus acidophilus , Bifidobacteria bifidum , and Bifidobacteria infantum ) in a rat model of colon cancer. This probiotic treatment altered the gut microbiota by promoting the growth of Lactobacilli to the detriment of other bacteria and reduced cancer via TLR2 signaling . Prebiotic feeding (galacto‐oligosaccharides) resulted in a decreased abundance of Helicobacters in wild‐type 129 mice .…”

Section: Gastric and Gut Microbiotamentioning

confidence: 99%

“…and severity of postprandial distress-like syndromes and treatment of FD patients with a yogurt containing a probiotic strain of Lactobacillus gasseri daily for a 12-week period reversed the dysbiosis and relieved their symptoms. 77 The administration of probiotics for correction of gastric dysbiosis may be a rational and promising direction for the treatment of FD. However, the microbiota of gastric aspirates is distinct from that in mucosal biopsies and does not provide a reliable representation of the mucosal-associated bacteria.…”

Section: Gastric and Gut Microbiotamentioning

confidence: 99%

See 1 more Smart Citation

Other Helicobacters, gastric and gut microbiota

et al. 2017

View full text Add to dashboard Cite

The current article is a review of the most important and relevant literature published in 2016 and early 2017 on non-Helicobacter pylori Helicobacter infections in humans and animals, as well as interactions between H. pylori and the microbiota of the stomach and other organs. Some putative new Helicobacter species were identified in sea otters, wild boars, dogs, and mice. Many cases of Helicobacter fennelliae and Helicobacter cinaedi infection have been reported in humans, mostly in immunocompromised patients. Mouse models have been used frequently as a model to investigate human Helicobacter infection, although some studies have investigated the pathogenesis of Helicobacters in their natural host, as was the case for Helicobacter suis infection in pigs. Our understanding of both the gastric and gut microbiome has made progress and, in addition, interactions between H. pylori and the microbiome were demonstrated to go beyond the stomach. Some new approaches of preventing Helicobacter infection or its related pathologies were investigated and, in this respect, the probiotic properties of Saccharomyces, Lactobacillus and Bifidobacterium spp. were confirmed.

show abstract

Gastric microbiota in the functional dyspepsia patients treated with probiotic yogurt

Cited by 67 publications

References 21 publications

Functional dyspepsia

Functional dyspepsia

The Ameliorating Effect of Lactobacillus gasseri OLL2716 on Functional Dyspepsia in Helicobacter pylori-Uninfected Individuals: A Randomized Controlled Study

Other Helicobacters, gastric and gut microbiota

Contact Info

Product

Resources

About